-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Neumora Therapeutics, Lowers Price Target to $5

Benzinga·07/13/2026 14:09:46
Listen to the news
RBC Capital analyst Brian Abrahams maintains Neumora Therapeutics (NASDAQ:NMRA) with a Outperform and lowers the price target from $7 to $5.